Free Articles, Free Web Content, Reprint Articles
Thursday, December 13, 2018
 
Free Articles, Free Web Content, Reprint ArticlesRegisterAll CategoriesTop AuthorsSubmit Article (Article Submission)ContactSubscribe Free Articles, Free Web Content, Reprint Articles
 

Measles Mumps and Rubella (MMR) Vaccines Market Opportunity Analysis, 2018 2026

Vaccine manufacturers are focusing on partnering with organizations such WHO, UNICEF, and GAVI Alliance to improve their vaccination programs, in order to reach the maximum population to offer vaccines.

Measles, mumps, and rubella are the three common contagious airborne diseases that are highly caused by virus transmitted by sneezing and coughing of the infected person, which could lead to serious complications or death among children. Vaccines of these diseases are sold as attenuated viral vaccines, manufactured in a lyophilised formulation, which requires reconstitution with water for injection diluent and are available in two forms i.e. monovalent as well as combinational vaccines. Combinational MMR vaccines comprises mixture of two or more viral strains.

Click To Continue Reading @ Measles Mumps and Rubella (MMR) Vaccines Market

These measles, mumps, and rubella vaccines are administered by subcutaneous injection to children as well as adults. It is generally administered to children aged 1 year and second dosage can be administered as early as one month after the first dose. According to CDC, two doses of measles, mumps and rubella vaccine are 97% effective against measles and 88% effective against mumps. One dose of measles, mumps, and rubella vaccine is 93% effective against measles, 78% effective against mumps, and 97% effective against rubella.

Currently, few vaccines available in the measles, mumps, and rubella vaccine market are sold under the trade name of M-M-R II, ProQuad, and Attenuvax by Merck Co. Inc.; Varilrix, Priorixtetra and MMR by GSK; Trimovax by Sanofi Pasteur and Tresivac by Serum Institute of India.

In spite of several governmental initiatives, measles is a leading cause of death among young children. Therefore, increasing success rate of vaccination programmes depends on government initiatives of each country. Some organizations are focusing on initiative, in order to reduce the prevalence of these diseases. For instance, GAVI Alliances has undertaken an initiative to provide vaccination in high-risk countries such as Afghanistan, Chad, Ethiopia, the Democratic Republic of the Congo, Nigeria and Pakistan. Similarly, in 2017, the Government of India launches Pan-India Measles-Rubella vaccination campaign, under which children ages from 9 months to 15 years are vaccinated to reduce the incidence of these disease in children. Such initiatives by various organizations and governments is expected to aid in growth of the market. Furthermore, development of combinational vaccines could aid in reducing cost and adverse effects by reducing the number of vaccination programme.

Dowload PDF Brochure of this Business Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1496

Key Vendors:

GlaxoSmithKline (Belgium), Merck & Co. Inc. (USA) and Serum Institute of India Ltd, among others.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
SeattleFree Articles, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Visit our news Website: https://www.coherenttimes.org/

Source: Free Articles from ArticlesFactory.com

ABOUT THE AUTHOR


About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.



Health
Business
Finance
Travel
Technology
Home Repair
Computers
Marketing
Autos
Family
Entertainment
Law
Education
Communication
Other
Sports
ECommerce
Home Business
Self Help
Internet
Partners


Page loaded in 0.440 seconds